OverviewSuggest Edit

Myriad Genetics is a molecular diagnostic company which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The Company offers molecular diagnostic tests, including DNA sequencing tests for hereditary breast, ovarian, colorectal and uterine cancer, a protein quantification test for assessing the disease activity of rheumatoid arthritis, RNA expression tests for assessing the aggressiveness of prostate cancer, diagnosing melanoma, and a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. It also provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.
TypePublic
Founded1991
HQSalt Lake City, US
Websitemyriad.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Jun 2019)2,600(+9%)
Job Openings201
Revenue (FY, 2018)$772.6 M
Share Price (Jun 2019)$24.1 (-3%)

Key People/Management at Myriad Genetics

Mark Capone

Mark Capone

President and CEO​
Patrick Burke

Patrick Burke

Executive Vice President, Emerging Products, Myriad Genetics
Bryan Dechairo

Bryan Dechairo

Executive Vice President, Clinical Development, Myriad Genetics, Inc.
Alexander Ford

Alexander Ford

President, Myriad Women's Health
Jayne Hart

Jayne Hart

Executive Vice President, Human Resources, Myriad Genetics, Inc.
Rishi Kacker

Rishi Kacker

Chief Technology Officer, Myriad Genetics, Inc.
Show more

Myriad Genetics Office Locations

Myriad Genetics has offices in Salt Lake City, South San Francisco, Austin, Mason and in 8 other locations
Salt Lake City, US (HQ)
320 Wakara Way
Austin, US
3300 Duval Rd
Mason, US
6960 Cintas Blvd
South San Francisco, US
341 Oyster Point Blvd
South San Francisco, US
180 Kimball Way
Issy-les-Moulineaux, FR
13 Rue Camille Desmoulins
Show all (13)

Myriad Genetics Financials and Metrics

Myriad Genetics Revenue

Myriad Genetics's revenue was reported to be $772.60 m in FY, 2018 which is a 0.4% increase from the previous period.
USD

Market capitalization (10-Jun-2019)

1.8b

Closing stock price (10-Jun-2019)

24.1
Myriad Genetics's current market capitalization is $1.8 b.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

740.5m769.9m772.6m

Revenue growth, %

2%4%0%

Cost of goods sold

157.3m171.2m177.2m

Gross profit

583.2m598.7m595.4m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

183.5m193.3m190.5m177.5m196.5m196.9m178.8m187.9m193.5m202.3m216.8m

Cost of goods sold

36.5m40.6m40.2m40.0m44.4m44.3m43.0m44.4m44.1m49.7m52.1m

Gross profit

147.0m152.7m150.3m137.5m152.1m152.6m135.8m143.5m149.4m152.6m164.7m

Gross profit Margin, %

80%79%79%77%77%78%76%76%77%75%76%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

68.5m102.4m110.9m

Accounts Receivable

91.7m90.2m98.3m

Prepaid Expenses

18.4m12.7m9.4m

Inventories

38.3m42.2m34.3m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

87.4m134.7m120.5m86.9m108.1m123.8m87.9m88.7m97.4m93.3m90.6m

Accounts Receivable

83.4m84.3m91.1m98.2m107.6m114.8m113.2m121.1m123.7m119.1m116.6m

Prepaid Expenses

5.6m9.7m21.1m12.2m12.1m9.5m9.5m9.8m10.1m11.5m12.5m

Inventories

34.3m29.1m25.3m53.9m51.3m47.4m38.9m38.2m33.4m35.9m33.3m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Depreciation and Amortization

26.8m48.3m54.4m73.0m

Inventories

(14.6m)(1.2m)7.9m8.0m

Accounts Payable

(3.0m)4.0m

Cash From Operating Activities

166.3m106.2m115.9m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Depreciation and Amortization

6.8m13.5m20.0m9.2m22.1m35.0m13.2m26.3m39.3m18.3m36.3m

Inventories

(9.2m)(4.1m)(200.0k)(13.0m)(10.4m)(6.5m)3.3m4.1m8.9m3.5m6.1m

Accounts Payable

(5.3m)(4.1m)(6.9m)(5.0m)(2.0m)2.0m400.0k3.0m(2.0m)(8.4m)(300.0k)

Cash From Operating Activities

29.8m81.9m127.8m(2.9m)28.5m69.6m23.5m56.5m68.0m7.8m45.6m
Show all financial metrics

Myriad Genetics Operating Metrics

FY, 2016FY, 2017FY, 2018Jan, 2019

Patients Tested to Date

2 m3 m3 m

Products

11

Tests Performed to Date

4 m

Scientific Publications to Date

1 k
Show all operating metrics

Myriad Genetics Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
CounsylMay 29, 2018$408.60 m
Myriad NeuroscienceAugust 03, 2016$351.60 m
Sividon DiagnosticsMay 31, 2016$56 m
Privatklinik Dr. Robert SchindlbeckFebruary 27, 2015$20.10 m
Crescendo BioscienceFebruary 04, 2014$270 m
Rules-Based MedicineApril 27, 2011$80 m
Javelin PharmaceuticalsDecember 18, 2009$95 m
NaturNorth TechnologiesApril 10, 2008
AssureRx Canada, Ltd
Assurex Health, Inc.
Show more

Myriad Genetics Revenue Breakdown

Embed Graph

Myriad Genetics revenue breakdown by business segment: 93.1% from Diagnostics and 6.9% from Other

Myriad Genetics Online and Social Media Presence

Embed Graph

Myriad Genetics News and Updates

Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm

SAN FRANCISCO, Aug. 19, 2019 /PRNewswire/ -- Hagens Berman notifies investors in Myriad Genetics, Inc. (NASDAQ: MYGN) of the firm's investigation of possible disclosure violations concerning its GeneSight® Psychotropic test, one of Myriad's most important products. If you invested in...

Myriad Genetics stock plummets 39% after lower-than-expected earnings, FDA questions

Shares of molecular-diagnostics firm Myriad Genetics Inc. plummeted 39% Wednesday morning after the company reported lower-than-expected fourth-quarter earnings and disclosed that the U.S. Food and Drug Administration had requested changes to one of its tests. On Tuesday afternoon, Myriad reported…

Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis Diagnostic System in Japan

BRACAnalysis Is Now Indicated as a Companion Diagnostic for Lynparza® (olaparib) in Women with Ovarian Cancer.read more

New Upcoming Trends for Global Clinical Genomics Market 2019 to 2025: Major Key Players - Abbott Laboratories, PerkinElmer Inc., Beckman Coulter Inc. (Danaher Corporation), Myriad Genetics Inc., Illumina Inc.

Clinic genomics also referred to as clinical genomics, is the study of clinical outcomes with genomic data. Posted via Industry Today. Follow us on Twitter @IndustryToday

Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results

SALT LAKE CITY, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal second-quarter 2019, provided an update on recent business highlig…

Medical And Diagnostic Laboratory Services Market 2019 Industry Analysis, Size, Share, Growth|RadNet, Quest Diagnostics, Inc., Myriad Genetics, Inc., OPKO Health, Inc

Medical And Diagnostic Laboratory Services Market Report aims to define, describe, and forecast on the basis of Market size, share, types, overview, top key vendors. This research report provides analysis and information according to market segments such as geography, technology and application. Pos…
Show more

Myriad Genetics Frequently Asked Questions

  • When was Myriad Genetics founded?

    Myriad Genetics was founded in 1991.

  • Who are Myriad Genetics key executives?

    Myriad Genetics's key executives are Mark Capone, Patrick Burke and Bryan Dechairo.

  • How many employees does Myriad Genetics have?

    Myriad Genetics has 2,600 employees.

  • Who are Myriad Genetics competitors?

    Competitors of Myriad Genetics include Foundation Medicine, Genomic Health and Ambry Genetics.

  • Where is Myriad Genetics headquarters?

    Myriad Genetics headquarters is located at 320 Wakara Way, Salt Lake City.

  • Where are Myriad Genetics offices?

    Myriad Genetics has offices in Salt Lake City, South San Francisco, Austin, Mason and in 8 other locations.

  • How many offices does Myriad Genetics have?

    Myriad Genetics has 13 offices.